AbCellera Biologics Inc.
ABCL
$2.34
-$0.055-2.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 27.44% | -78.63% | -20.97% | -1.25% | -57.73% |
| Total Depreciation and Amortization | -298.70% | 416.87% | 424.21% | -4.97% | 30.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.78% | -174.20% | -247.64% | 61.45% | -31.51% |
| Change in Net Operating Assets | 957.56% | -180.04% | -129.14% | -17.75% | -95.14% |
| Cash from Operations | 59.21% | -27,147.17% | -250.56% | 5.34% | -163.44% |
| Capital Expenditure | -8.31% | 8.93% | 26.07% | -61.11% | -17.04% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 618.93% | 194.42% | 1,104.42% | 140.15% | -109.00% |
| Cash from Investing | 246.79% | 128.92% | 251.49% | 119.99% | -42.55% |
| Total Debt Issued | 17.28% | -52.71% | -- | -- | 1,341.26% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -11.33% | 38.02% | 82.04% | -- |
| Repurchase of Common Stock | -46.30% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4.32% | 1.08% | -315.29% | 80.49% | -- |
| Cash from Financing | 10.01% | -52.56% | 532.70% | 718.12% | 978.80% |
| Foreign Exchange rate Adjustments | -302.25% | 134.52% | -105.40% | -266.67% | 193.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 175.92% | -195.86% | 286.42% | 94.98% | -368.51% |
